| Linda J George, CNM | |
|
701 Medical Park Dr, Ste 202, Hartsville, SC 29550-4777 | |
| (843) 339-9222 | |
| (843) 339-2830 |
| Full Name | Linda J George |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 27 Years |
| Location | 701 Medical Park Dr, Hartsville, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316976186 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartsville Medical Group, Llc | 7012062714 | 35 |
News Archive
Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.
Some may assume that low-income residents of run-down, crime-ridden neighborhoods do not care about their communities. However, research from the University of Missouri suggests otherwise.
Cancer researchers have been limited by current imaging technology in their ability to detect not only structure and function of tumors, but also tumor cell circulation. A technology proposed by Lihong Wang, PhD, at Washington University in St. Louis, may hold the key to reaching this goal.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
› Verified 6 days ago
| Entity Name | Hartsville Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598995300 PECOS PAC ID: 7012062714 Enrollment ID: O20090902000027 |
News Archive
Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.
Some may assume that low-income residents of run-down, crime-ridden neighborhoods do not care about their communities. However, research from the University of Missouri suggests otherwise.
Cancer researchers have been limited by current imaging technology in their ability to detect not only structure and function of tumors, but also tumor cell circulation. A technology proposed by Lihong Wang, PhD, at Washington University in St. Louis, may hold the key to reaching this goal.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Linda J George, CNM 701 Medical Park Dr, Ste 202, Hartsville, SC 29550-4777 Ph: (843) 339-9222 | Linda J George, CNM 701 Medical Park Dr, Ste 202, Hartsville, SC 29550-4777 Ph: (843) 339-9222 |
News Archive
Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.
Some may assume that low-income residents of run-down, crime-ridden neighborhoods do not care about their communities. However, research from the University of Missouri suggests otherwise.
Cancer researchers have been limited by current imaging technology in their ability to detect not only structure and function of tumors, but also tumor cell circulation. A technology proposed by Lihong Wang, PhD, at Washington University in St. Louis, may hold the key to reaching this goal.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
› Verified 6 days ago